Search results

  1. Wyva

    Medscape article: No Evidence Supports Using Graded Exercise for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

    by Miriam E. Tucker “We face a mismatch around physical activity between established medical practice and what the evidence actually shows. For decades, medicine has worked from the idea that physical activity promotes health and recovery…This underlying idea continues to underpin many...
  2. Wyva

    Mitochondrial and lysosomal signaling orchestrates heterogeneous metabolic states of regulatory T cells, 2025, Saravia et al

    Editor’s summary Lymphocytes, including regulatory T (Treg) cells, tune their metabolism to support their immunological functions. However, the molecular events controlling Treg cell metabolic reprogramming during inflammation are not fully understood. Using a mouse model of acute inflammation...
  3. Wyva

    HLA and pathogens in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and other post-infection conditions, 2025, Georgopoulos et al

    Apostolos P. Georgopoulos, Lisa M. James & Philip K. Peterson Abstract Viral infections have been widely implicated in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) pathogenesis. Recent evidence has also identified certain Human Leukocyte Antigen (HLA) alleles that are...
  4. Wyva

    Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome, 2024, Walitt et al

    I also saw this article about the response of Wallitt et al., so maybe they have sent out a press release (about their own response naturally): Myalgic Encephalomyelitis: Beyond Effort and Deconditioning 'In a compelling and much-needed scientific dialogue, a fresh reply has emerged in the...
  5. Wyva

    Guardian piece on"Lyme"

    Letter responses to the article in the Guardian: Failed by the NHS on chronic fatigue illness One of them is from Prof Paul Garner, Dr Maria Pedersen and Dr Alastair Miller (who would have thought...): "Milly’s exhaustion is typical of a group of conditions known as “persistent physical...
  6. Wyva

    How would an Average pwME/carer (no biology knowledge or access to S4ME) be able to tell when a mechanism has been discovered vs bio “memes” and hype?

    There have been several examples, for example with some organizations (Doctors with ME is something I remember but there were probably more), sometimes researchers or people doing their PhD come to S4ME and take scientific criticism very badly, one example was a questionnaire recently developed...
  7. Wyva

    How would an Average pwME/carer (no biology knowledge or access to S4ME) be able to tell when a mechanism has been discovered vs bio “memes” and hype?

    I do delete posts and even ban repeat offenders from my group when they obviously break the rules. But very often things are not so clear-cut, especially with newer users who may be just naive and inexperienced. I need to cut people some slack, because as I said, my group is quite young, and...
  8. Wyva

    How would an Average pwME/carer (no biology knowledge or access to S4ME) be able to tell when a mechanism has been discovered vs bio “memes” and hype?

    This is a constant problem in my group. It was started in the first year of covid and most people in my group are covid long haulers, so mostly newer patients looking for a cure, blindly trusting every doctor who just mentions "chronic fatigue syndrome" and not many people who already tried...
  9. Wyva

    Guardian piece on"Lyme"

    It is probably the test from the German Armin Labs, whose tests are known to overdiagnose people with Lyme (I have a memory from this forum that some very healthy journalist tried the test as an experiment once and it came back positive). A lot of people are told in alt med/Lyme circles that the...
  10. Wyva

    Metaresearch on patient-reported outcomes in trial protocols and results publications suggested large outcome reporting bias, 2025, Heravi, Busse et

    Ala Taji Heravi ∙ Dmitry Gryaznov ∙ Jason W. Busse ∙ Christof Manuel Schönenberger ∙ Belinda von Niederhäuserne ∙ Lena Hausheer ∙ Manuela Covino ∙ Johannes M. Schwenke ∙ Selina Epp ∙ Alexandra Griessbach ∙ Malena Chiaborelli ∙ Arnav Agarwal ∙ Szimonetta Lohner ∙ Julian Hirt ∙ Stefan...
  11. Wyva

    Cardiovascular disease prevention and management in COVID-19: a clinical consensus statement of the European Association of (...), 2025, Vassiliou et

    Full title: Cardiovascular disease prevention and management in COVID-19: a clinical consensus statement of the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging, the Association of Cardiovascular Nursing & Allied Professions, the European...
  12. Wyva

    Upper respiratory tract immunization with Pam2Cys-adjuvanted spike protein vaccine achieves sterilizing protection against SARS-CoV-2, 2025, Stewart +

    Abstract Injected COVID-19 vaccines protect against severe disease, but do not induce robust mucosal immune responses. Nasal vaccines offer the advantage of local immunity to block viral infection and transmission. Previously we showed immunization of a Pam2Cys-adjuvanted SARS-CoV-2 vaccine to...
  13. Wyva

    Translating S4ME Fact Sheets into Mandarin Chinese

    About mono/glandular fever: it is the same in Hungary. I never heard of it until I got mono myself in my early thirties (leading to my ME/CFS). I don't remember any high school/college kids I knew who had it. Whenever I tell my story, I need to explain to people what mono is, they don't know...
  14. Wyva

    Age-Related Changes in the Clinical Picture of Long COVID, 2025, Fain, Hornig et al

    ABSTRACT Background This study evaluated the impact of aging on the frequency and prevalent symptoms of Long COVID, also termed post-acute sequelae of SARS-CoV-2, using a previously developed Long COVID research index (LCRI) of 41 self-reported symptoms in which those with 12 or more points...
  15. Wyva

    Early Growth Response Gene 1 Benefits Autoimmune Disease by Promoting Regulatory T Cell Differentiation as a Regulator of Foxp3, 2025, Yang et al

    Abstract Foxp3+ regulatory T (Treg) cells, as one of the subtypes of CD4+ T cells, are the crucial gatekeeper in the pathogenesis of self-antigen reactive diseases. In this context, we demonstrated that the selective ablation of early growth response gene 1 (Egr-1) in CD4+ T cells exacerbated...
Back
Top Bottom